# Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

> **NCT00002965** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **BIOLOGICAL:** Recombinant Interferon Alfa (INF alpha)

## Key facts

- **NCT ID:** NCT00002965
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-01
- **Primary completion:** 2003-03
- **Final completion:** 2003-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002965, "Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00002965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*